Our Board of Directors is elected to the Board by our shareholders each year. We currently have seven Board members, five of whom are "independent" under the rules of the NASDAQ stock exchange. Our Directors are:
Ronald D. Henriksen
Chairman
Ronald D. Henriksen joined Cytori Therapeutics as Director in October 2002. He was also a board member of Cytori’s predecessor, StemSource, Inc. Mr. Henriksen has more than 30 years of experience in healthcare, pharmaceutical, biotechnology and consulting and venture capital industries. He currently serves as Chief Investment Officer of Twilight Ventures, LLC, and Chairman of the Board of Semafore Pharmaceuticals and EndGenitor Technologies, the latter of which he is also Founder and President. For more than 20 years, Mr. Henriksen held executive positions with Eli Lilly, where he served as Managing Director for Brazil, Mexico and Central America, and negotiated international contracts through Lilly Business Development. Additional Board Directorships include board member positions of PreMD, Inc. and BioStorage Technologies. Mr. Henriksen received his B.S. in Industrial Administration from Iowa State University and an M.B.A. with distinction from Harvard Business School. He also served as an officer for four years in the U.S. Navy.
David Rickey
Director
David Rickey has served as a Director of Cytori Therapeutics since November 1999. From 1996 to March 2005, Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation, which provides high-performance, high-bandwidth silicon solutions for optical networks. Mr. Rickey served as Chairman of the Board of Applied Micro Circuits Corporation, as a Director of AMI Semiconductor, Inc., and is currently a member of the board of Netlist. Mr. Rickey holds two B.S. degrees, from Marietta College and Columbia University, and an M.S. from Stanford University.
E. Carmack Holmes
Director
E. Carmack Holmes, M.D., joined Cytori Therapeutics as Director in August 2003. Dr. Holmes served as the Surgeon-in-Chief of the University of California Los Angeles (UCLA) Medical Center and holds the position of William P. Longmire, Jr. Professor and Chairman, Department of Surgery, UCLA School of Medicine. He joined UCLA in 1973 and has held professorial positions in the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years. He served as Vice-Chairman for five years prior to holding the positions of Chairman and Surgeon-in-Chief for the past ten years. Dr. Holmes is the recipient of numerous awards and grants and his professional memberships include the American Surgical Association, the American College of Surgeons and the Association for Academic Surgeons. He has authored 250 medical publications throughout his career and has been an internationally invited lecturer for over 25 years. His surgical training was conducted at The Johns Hopkins University and the National Cancer Institute at the National Institutes of Health (NIH). Dr. Holmes graduated from Duke University and holds an M.D. from the University of North Carolina Medical School.
Paul W. Hawran
Director
Paul W. Hawran joined Cytori Therapeutics as Director in February 2005. Mr. Hawran has served as Chief Financial Officer of Sequenom, Inc., since April 2007. He previously served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. starting in January 2001. Prior to that, he served as Senior Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. for five years and Vice President and Chief Financial Officer for three years prior. Mr. Hawran has also held executive management positions at SmithKline Beecham (now Glaxo SmithKline), most recently as Vice President and Treasurer. Prior to joining SmithKline (Beecham?) in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John's University and an M.S. in taxation from Seton Hall University. He is a certified public accountant and a member of the American Institute of Certified Public Accountants.
Richard J. Hawkins
Director
Richard J. Hawkins joined us as Director in December 2007. Since 2004, he has served as the Chairman and CEO of LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. In addition to his role as Chairman of the Board for LabNow Inc. Mr. Hawkins holds a B.S. in biology from Ohio University.
Christopher J. Calhoun
Chief Executive Officer
Christopher J. Calhoun is a co-founder of Cytori Therapeutics and has served as the Company's Chief Executive Officer, Vice-Chairman and Director of the Board since 1997. He previously served as President from 1996 through 1998. Mr. Calhoun is the co-inventor on multiple U.S. and International patents for medical devices and implant instrumentation. Mr. Calhoun was also involved in research and management for the Plastic Surgery Bone Histology and Histometry Laboratory at the University of California, San Diego. Mr. Calhoun is a co-founder and Chairman of the Board of Leonardo MD, and has previously served on the Board of Directors of StemSource, Inc. Mr. Calhoun received a B.A. from the University of California, San Diego and an M.B.A. from the University of Phoenix.
Marc H. Hedrick
President
Dr. Marc H. Hedrick was appointed President in May 2004. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas.